|
|
| Year : 1998 | Volume
: 19
| Issue : 4 | Page : 121-128 |
|
|
Role of paclitaxel as a single agent and in combination with iforfamide in advanced head and neck cancer
VR Pai, K Devendra, AT Mazumdar, DM Parikh, RC Mistry, AR Faikh
Department of Medical Oncology and Surgical Oncology, Tata memorial Hospital, Parel, Mumbai
Correspondence Address:
VR Pai
Department of Medical Oncology and Surgical Oncology, Tata memorial Hospital, Parel, Mumbai
 Source of Support: None, Conflict of Interest: None  | Check |
|
|
|
PURPOSE: To evaluate the efficacy of paclitaxel as a single agent and in combination with ifosfamide in advanced or recurrent head and neck cancer patients. PATIENTS AND METHODS: Thirty one male patients with squamous cell carcinoma were entered in this study. Seven patients received paclitaxel (200 mg/m2), as a single agent and twenty four patients received a fixed dose of ifosfamide (1.5 gm/m2) and one of three escalating dose levels of paclitaxel. In group 1-100 mg/m2, in group 11-140 mg/m2, in group 111-175 mg/m2 paclitaxel was given. Premedication was given prior to paclitaxel (dexamethasone, phenargan, ranitidine). The cycles were repeated at an interval of 4 weeks for a total of three cycles. RESULTS: Six evaluable patients received paclitaxel (200 gm/m2) as a single agent. Ifosfamide and escalating doses of paclitaxel. In group 1(100 mg/m2) five patients, in group II (140 mg/m2) seven patients and group III (175 mg/m2) twelve patients were treated. Whereas no response was observed in group I and only one partial response in group II, four complete and four partial responses were observed in group III. There was no dose limiting hematological and neurotoxicity observed. One patient died two days after the first cycle due to cardiac failure and respiratory distress. CONCLUSION: Paclitaxel shows consistent antitumour effect advanced and recurrent head and neck cancer patients as a single agent and in combination with Ifosfamide. |
|
|
|
| [PDF Not available]* |
|
 |
|
